In HCC cells, Notch3 signaling contributes to doxorubicin resistance by inhibiting p53 expression, doxorubicin uptake and DNA damage, which can be reversed by Notch3 depletion (Giovannini et al., 2009). Here, NOTCH3 is linked to hepatocellular carcinoma.